| Document |
Document Title |
|
WO/2021/081315A1 |
Cryptosporidium is a leading contributor to early childhood mortality, and fully effective treatment for this important infectious disease is lacking. A bicyclic azetidine compound series is disclosed having potent in vitro activity agai...
|
|
WO/2021/073586A1 |
Disclosed are a decoquinate liposome, a preparation method therefor and a use thereof. The preparation raw materials for the decoquinate liposome comprise the following components in parts by weight: 1 part of decoquinate and 2-20 parts ...
|
|
WO/2021/076922A1 |
This disclosure features niclosamide compounds (or pharmaceutically acceptable salts and/or co-crystals thereof, e.g., niclosamide), having one or more properties that include, but are not limited to: a particular purity (e.g., a chemica...
|
|
WO/2021/074452A1 |
The present invention relates to pharmaceutical preparations containing as active ingredients 3-N-formylhydroxylaminopropylphosphonic acid derivatives or 3-N-acetylhydroxylaminopropylphosphonic acid derivatives in combination with clinda...
|
|
WO/2021/069569A1 |
The present invention relates to novel heteroaryl-triazole compounds of the general formula (I), in which the structural elements X, Y, R1, R2, R3, R4 and R5 have the meaning given in the description, to formulations and compositions com...
|
|
WO/2021/068080A1 |
Described herein is an immunogenic fusion protein comprising: an immunogenic peptide or an immunogenic variant thereof, the immunogenic peptide comprising the following motifs: - KQPAa; QPAKa; PAKQa; or AKQPa; - NPDPb; PNPDb; DPNPb; or P...
|
|
WO/2021/069567A1 |
The present invention relates to novel heteroaryl-triazole compounds of the general formula (I), in which the structural elements X, Y, R1, R2, R3a, R3b, R4 and R5 have the meaning given in the description, to formulations and compositio...
|
|
WO/2021/065885A1 |
A compound represented by general formula (I) or a salt thereof. (In the formula, R1 to R5, X, Y, Q1 and Q2 are as defined in the description.)
|
|
WO/2021/064217A1 |
The present document discloses methods and means for treating and/or preventing ectoparasite infestations and/or gill parasite infection in teleosts by the administration of probiotic bacteria to the teleosts.
|
|
WO/2021/067261A1 |
Provided are conjugates comprising a knottin peptide comprising an engineered loop that binds to a cell surface molecule, and an immunostimulant conjugated to the knottin peptide via a linker. According to some embodiments, the immunosti...
|
|
WO/2021/067967A1 |
The present invention relates to pyrazolo[3,4-b]pyridine compounds. The present invention further relates to methods for inhibiting Plasmodium comprising contacting Plasmodium with pyrazolo[3,4-b]pyridine compounds described herein. Also...
|
|
WO/2021/067801A1 |
This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or prodrug, and/or tautomer, and/or drug combination of the compound) that inhibit (e.g., antagoniz...
|
|
WO/2021/067791A1 |
This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that inhibit (e.g., antagonize) Stimulator of Interferon Genes...
|
|
WO/2021/060862A1 |
The present invention relates to a composition containing fucoidan as an active ingredient and, more specifically, to: a pharmaceutical composition for preventing or treating malaria, containing fucoidan as an active ingredient; and a di...
|
|
WO/2021/047210A1 |
Provided is an immunization-purpose suspending agent, comprising the following raw materials in parts by weight: 15-40 parts of sodium alginate, 5-20 parts of guar gum, 2-10 parts of blow-dried powder, 1-10 parts of a surfactant, and 12-...
|
|
WO/2021/049596A1 |
The present invention addresses the problems of: damage by pests still being extensive in crop production such as agriculture and horticulture; the need to develop and provide a novel agricultural and horticultural insecticide due to the...
|
|
WO/2021/047565A1 |
A method for preparing and detecting an (R) or (S) configuration of 1,2,3,4-tetrahydro-isoquinoline-1-carboxylic acid, and a composition thereof, and for preparing (R)-praziquantel and a key intermediate thereof. An (R) or (S) acid is pr...
|
|
WO/2021/049597A1 |
The present invention addresses the problem of developing and providing a novel insecticide agent for agricultural or horticultural use on the basis of factors in the production of agricultural and horticultural crops, such as the fact t...
|
|
WO/2021/049595A1 |
Pests still cause major damage, and pests occur that resistant to existing pesticides, so the present invention addresses the problem in crop production, including agriculture and horticulture, of developing and providing a novel agricul...
|
|
WO/2021/042194A1 |
Despite recent efforts to eradicate malaria worldwide, this parasitic disease is still considered to be a major public health issue, with a total of 219 million cases of malaria and 435,000 deaths in 2017. However, after a decade of use,...
|
|
WO/2021/037289A2 |
Disclosed are a recombinant fusion polypeptide, a preparation method therefor, and a use thereof. A recombinant fusion polypeptide, said recombinant fusion polypeptide being expressed as the following general formula: X-linker1-Y, Y-link...
|
|
WO/2021/038250A1 |
There is discussed nematode antigens capable of causing an immune response in a host such that a protective effect is provided to the host in relation to the nematode. Antigens, compositions for the treatment of parasitic nematode infect...
|
|
WO/2021/037291A2 |
Disclosed is a use of a fusion polypeptide having multifunctional activities. The fusion polypeptide having multifunctional activities is characterized in that the polypeptide comprises the following domain: Pro-Arg-Cys-X-Y-Gly-Glu, wher...
|
|
WO/2021/032687A1 |
A series of 2-imino-6-methylhexahydropyrimidin-4-one derivatives, and analogues thereof, substituted in the 6-position by an arylcarbonylaminophenyl or heteroarylcarbonylaminophenyl moiety, being potent inhibitors of the growth and propa...
|
|
WO/2021/032861A1 |
The invention relates to combinations of urolithins with therapeutic agents, particularly combinations of urolithins with immunotherapy treatments, such as immune checkpoint blockage therapies, such as PD-1 antagonists. The invention als...
|
|
WO/2021/034963A1 |
T. gondii proteins MIC1 and MIC4 are components of excretory/secretory antigens (ESA) that elicit delayed type hypersensitivity (DTH) responses in infected animals. These antigens are capable of inducing IFN- g secretion by splenic T cel...
|
|
WO/2021/033159A1 |
The present disclosure relates to pyrazino [1,2-b]quinazoline-3,6-diones compounds, in particular it relates to pyrazino [1,2-b]quinazoline-3,6-diones compounds having antibacterial activity and/or antimalarial activity.
|
|
WO/2021/028479A1 |
The present invention relates to a composition comprising tigolaner and, optionally endoparasiticidal agents, a method for its manufacture and its use as a medicament for controlling parasites.
|
|
WO/2021/028696A1 |
Described herein are pharmaceutical compositions and contact lens solutions comprising an Acanthamoeba encystation inhibitor such as a cationic quaternary ammonium compound and a physiologically or pharmaceutically acceptable carrier or ...
|
|
WO/2021/027502A1 |
Methods of treating malaria comprising administration of compounds of Formula (I') or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the variables are as defined herein. It also provides uses of the com...
|
|
WO/2021/030162A1 |
The present invention relates to salt forms of the PD-1/PD-L1 inhibitor (R)-1-((7-cyano-2-(3'-(3-(((R)-3-hydroxypyrrolidin-1-yl)meth
yl)-1,7-naphthyridin-8-ylamino)-2,2'-dimethylbiphenyl-3-yl)b
enzo[d]oxazol-5-yl)methyl)pyrrolidine-3-car...
|
|
WO/2021/026884A1 |
Methods for treating malaria comprises administration of compounds of Formula (I) or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the variables are as defined herein. It also provides uses of the comp...
|
|
WO/2021/023886A1 |
Liquid dressing compositions liquid for veterinary use in the treatment or prevention of infection and/or wounds are described that comprise shellac, an anti-infective metal active and a solvent. The compositions are capable of forming a...
|
|
WO/2021/025020A1 |
Provided is a pharmaceutical agent that increases the efficiency of drug absorption through a mucosal epithelial layer.　This pharmaceutical agent for transmucosal administration contains, as an active ingredient, a pharmaceutical agent...
|
|
WO/2021/023885A1 |
Liquid dressing compositions liquid for use in the treatment or prevention of infection and/or wounds are described that comprise shellac, an anti-infective metal active and a solvent. The compositions are capable of forming a barrier wh...
|
|
WO/2021/017475A1 |
Disclosed is an ophthalmic pharmaceutical composition containing a cyclosporine, a preparation method and use thereof. The ophthalmic pharmaceutical composition expressed by weight percentages comprises 0.01%-0.5% of a cyclosporine, 0.2%...
|
|
WO/2021/019506A1 |
The present invention relates to a composition comprising at least one amino acid, (ii) a controlled release lipid matrix, and optionally (ill) at least one acceptable pharmaceutical or food grade additive and/or excipient. Furthermore, ...
|
|
WO/2021/019067A1 |
The invention relates to a veterinary composition comprising paromomycin or a pharmaceutically acceptable salt thereof for use in the prevention and/or treatment of cryptosporidiosis in a non-human mammal, wherein the composition is admi...
|
|
WO/2021/019510A1 |
The present invention relates to a composition for use in a method for the treatment of an amino acid deficiency to a non-mammalian monogastric animal, such as a poultry animal, a fish or a crustacean, wherein said composition comprises ...
|
|
WO/2021/018839A1 |
The present invention covers new isoquinoline compounds of general formula (I), in which A, R1, R2, R3, R4, R5, R6, and Q are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compou...
|
|
WO/2021/014415A2 |
The present invention relates to compounds of formula (I). The compounds may be used to modulate the acetyl coenzyme A synthetase short chain 2 (ACSS2) protein and may thereby treat, ameliorate or prevent a disease selected from cancer, ...
|
|
WO/2021/016509A1 |
An immunogen useful for treating malaria generally includes an immunogenic carrier and an antigenic malaria circumsporozoite protein (CSP) peptide that includes the peptide NPDPNANPNVDPNAN (amino acids 5-19 of SEQ ID NO:1) linked to the ...
|
|
WO/2021/013720A1 |
The present invention relates to novel heteroaryl-triazole and heteroaryl-tetrazole compounds of the general formula (I), in which the structural elements R1, R2, R3, R4 and R5 have the meaning given in the description, to formulations a...
|
|
WO/2021/008512A1 |
The present invention provides a compound having N-myristoyltransferase (NMT) inhibitor activity or a pharmaceutically acceptable salt thereof and a preparation method therefor. The present invention also relates to use of such compound ...
|
|
WO/2021/009888A1 |
The purpose of the present invention is to provide a pediculicide which is not so pungent and scarcely causes side effects even if directly applied to the human skin as an external preparation and which can control lice. This problem can...
|
|
WO/2021/010843A1 |
Described herein are transdermal solvent systems comprising at least one active agent in solution in a base solution, the base solution comprising at least one fatty acid ester compound, at least one monoterpene compound and a co-solvent...
|
|
WO/2021/009050A1 |
The present invention relates to a composition comprising bacteria of the Delftia genus, specifically a composition comprising Delftia tsuruhatensis as well as the bacteria itself for use in the prevention of malaria transmission and met...
|
|
WO/2021/011503A1 |
Herein is described a method devised to cryopreserve mosquito eggs, viable upon subsequent thawing. The method reproducibly yields >25% hatched first instar larvae of Anopheles-species mosquitoes from cryopreserved eggs. The majority of ...
|
|
WO/2021/001697A1 |
The invention relates to novel boric acid-containing peptidomimetics I, (I) acting as inhibitors of the malaria subtilisin-related serine protease (SUB). They are useful as medicinal preparations or as ingredients for the treatment of ma...
|
|
WO/2021/001351A1 |
The present invention relates to an antibody binding to a peptide comprising an amino acid sequence NANP (SEQ ID NO:1) and to at least one peptide comprising an amino acid sequence selected from NVDP (SEQ ID NO:2), NPDP (SEQ ID NO:3), an...
|
